特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
923884

核医学/放射性医薬品の世界市場 - 2024年までの予測:診断用 (SPECT・PET)、治療用 (ベータ放射体、アルファ放射体、小線源治療)

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 231 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.37円
核医学/放射性医薬品の世界市場 - 2024年までの予測:診断用 (SPECT・PET)、治療用 (ベータ放射体、アルファ放射体、小線源治療)
出版日: 2020年01月27日
発行: MarketsandMarkets
ページ情報: 英文 231 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

核医学市場は、2019年の約41億米ドルから、2024年までに52億米ドルに達し、予測期間中のCAGRで4.7%の成長が予測されています。市場成長を促進する重要な要因は、癌・心血管疾患の発生率と有病率の増加、Mo-99の需給ギャップを縮小するための取り組みです。しかし、放射性医薬品の半減期は短く、採用の可能性が減り、病院の予算削減や高額な設備費により、エンドユーザーの一部は核医学に依存することが難しくなっています。これらの要因により、予測期間中の核医学市場の成長を妨げることが予想されます。

当レポートでは、世界の核医学/放射性医薬品市場について調査分析し、市場概要、産業動向、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

923884_4.4 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019 VS. 2024_FIGURE 13

目次

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 核医学市場の概要
  • 北米 - 核医学市場:種類別、国別
  • 診断処置市場:種類別
  • 治療用核医学市場:種類別

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題

第6章 核医学/放射性医薬品市場:種類別

  • イントロダクション
  • 診断用核医学
    • SPECT放射性医薬品
    • PET放射性医薬品
  • 治療用核医学
    • アルファ放射体
    • ベータ放射体
    • 小線源治療用同位体

第7章 核医学/放射性医薬品市場:適応別

  • イントロダクション
  • 診断用途
    • SPECT
    • PET
  • 治療用途
    • 甲状腺
    • 骨転移
    • 内分泌腫瘍
    • リンパ腫
    • その他

第8章 核医学/放射性医薬品市場:線量の評価

  • イントロダクション
  • 診断処置
    • SPECT
    • PET
  • 治療処置
    • ベータ放射体
    • アルファ放射体
    • 小線源治療

第9章 核医学/放射性医薬品市場:地域別

  • イントロダクション
  • 北米
  • アジア太平洋地域
  • 欧州
  • その他の地域

第10章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合リーダーシップマッピング
  • 競合シナリオ

第11章 企業プロファイル

  • CARDINAL HEALTH
  • CURIUM
  • GE HEALTHCARE
  • LANTHEUS MEDICAL IMAGING, INC.
  • BAYER AG
  • BRACCO IMAGING S.P.A.
  • ECZACIBASI-MONROL NUCLEAR PRODUCTS
  • NORDION, INC. (A SUBSIDIARY OF STERIGENICS INTERNATIONAL)
  • ADVANCED ACCELERATOR APPLICATIONS (AAA) (A PART OF NOVARTIS)
  • NTP RADIOISOTOPES SOC, LTD.
  • JOINT STOCK COMPANY ISOTOPE (JSC ISOTOPE)
  • NORTHSTAR MEDICAL RADIOISOTOPES, LLC
  • ECKERT & ZIEGLER
  • JUBILANT DRAXIMAGE, INC. (A SUBSIDIARY OF JUBILANT PHARMA)
  • PHARMALOGIC
  • INSTITUTE OF ISOTOPES CO., LTD.
  • SINOTAU PHARMACEUTICALS GROUP
  • ISOTOPIA MOLECULAR IMAGING LIMITED
  • SHINE MEDICAL TECHNOLOGIES
  • GLOBAL MEDICAL SOLUTIONS, LTD.
  • RIGHT TO WIN

第12章 付録

図表

LIST OF TABLES

  • TABLE 1 NEW REACTORS EXPECTED TO OPEN DURING THE FORECAST PERIOD
  • TABLE 2 NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 3 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 4 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 5 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 6 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 7 APAC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 8 ALTERNATIVES TO COMMON TC-99M-BASED DIAGNOSTIC PROCEDURES IN THE FACE OF SEVERE TC-99M SHORTAGES
  • TABLE 9 SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 10 SPECT RADIOPHARMACEUTICALS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 11 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 12 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 13 APAC: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 14 TC-99M MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 15 NORTH AMERICA: TC-99M MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 16 EUROPE: TC-99M MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 17 APAC: TC-99M MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 18 I-123 MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 19 NORTH AMERICA: I-123 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 20 EUROPE: I-123 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 21 APAC: I-123 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 22 TI-201 MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 23 NORTH AMERICA: TI-201 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 24 EUROPE: TI-201 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 25 APAC: TI-201 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 26 GA-67 MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 27 NORTH AMERICA: GA-67 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 28 EUROPE: GA-67 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 29 APAC: GA-67 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 30 OTHER SPECT ISOTOPES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 31 NORTH AMERICA: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 32 EUROPE: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 33 APAC: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 34 PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 35 PET RADIOPHARMACEUTICALS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 36 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 37 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 38 APAC: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 39 F-18 MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 40 NORTH AMERICA: F-18 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 41 EUROPE: F-18 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 42 APAC: F-18 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 43 RB-82 MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 44 NORTH AMERICA: RB-82 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 45 EUROPE: RB-82 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 46 APAC: RB-82 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 47 OTHER PET ISOTOPES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 48 NORTH AMERICA: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 49 EUROPE: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 50 APAC: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 51 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 52 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 53 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 54 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 55 APAC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 56 RA-223 MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 57 NORTH AMERICA: RA-223 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 58 EUROPE: RA-223 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 59 APAC: RA-223 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 60 BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 61 BETA EMITTERS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 62 NORTH AMERICA: BETA EMITTERS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 63 EUROPE: BETA EMITTERS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 64 APAC: BETA EMITTERS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 65 I-131 MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 66 NORTH AMERICA: I-131 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 67 EUROPE: I-131 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 68 APAC: I-131 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 69 Y-90 MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 70 NORTH AMERICA: Y-90 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 71 EUROPE: Y-90 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 72 APAC: Y-90 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 73 SM-153 MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 74 NORTH AMERICA: SM-153 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 75 EUROPE: SM-153 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 76 APAC: SM-153 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 77 LU-177 MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 78 NORTH AMERICA: LU-177 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 79 EUROPE: LU-177 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 80 APAC: LU-177 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 81 RE-186 MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 82 NORTH AMERICA: RE-186 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 83 EUROPE: RE-186 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 84 APAC: RE-186 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 85 OTHER BETA EMITTERS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 86 NORTH AMERICA: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 87 EUROPE: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 88 APAC: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 89 BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 90 BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 91 NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 92 EUROPE: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 93 APAC: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 94 I-125 MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 95 NORTH AMERICA: I-125 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 96 EUROPE: I-125 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 97 APAC: I-125 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 98 IR-192 MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 99 NORTH AMERICA: IR-192 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 100 EUROPE: IR-192 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 101 APAC: IR-192 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 102 PD-103 MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 103 NORTH AMERICA: PD-103 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 104 EUROPE: PD-103 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 105 APAC: PD-103 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 106 CS-131 MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 107 NORTH AMERICA: CS-131 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 108 EUROPE: CS-131 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 109 APAC: CS-131 MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 110 OTHER BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 111 NORTH AMERICA: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 112 EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 113 APAC: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 114 NUCLEAR MEDICINE MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 115 DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 116 SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 117 SPECT APPLICATIONS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 118 SPECT CARDIOLOGY APPLICATIONS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 119 SPECT BONE SCAN APPLICATIONS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 120 SPECT THYROID APPLICATIONS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 121 SPECT PULMONARY SCAN APPLICATIONS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 122 OTHER SPECT APPLICATIONS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 123 PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 124 PET APPLICATIONS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 125 PET ONCOLOGY APPLICATIONS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 126 PET CARDIOLOGY APPLICATIONS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 127 PET NEUROLOGY APPLICATIONS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 128 OTHER PET APPLICATIONS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 129 THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 130 THERAPEUTIC APPLICATIONS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 131 THERAPEUTIC APPLICATIONS MARKET FOR THYROID INDICATIONS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 132 THERAPEUTIC APPLICATIONS MARKET FOR BONE METASTASIS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 133 THERAPEUTIC APPLICATIONS MARKET FOR ENDOCRINE TUMORS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 134 THERAPEUTIC APPLICATIONS MARKET FOR LYMPHOMA, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 135 THERAPEUTIC APPLICATIONS MARKET FOR OTHER INDICATIONS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 136 NUCLEAR MEDICINE MARKET, BY PROCEDURE, 2017-2024 (THOUSAND PROCEDURES)
  • TABLE 137 NUCLEAR MEDICINE MARKET, BY REGION, 2017-2024 (THOUSAND PROCEDURES)
  • TABLE 138 DIAGNOSTIC PROCEDURES MARKET, BY TYPE, 2017-2024 (THOUSAND PROCEDURES)
  • TABLE 139 DIAGNOSTIC PROCEDURES MARKET, BY REGION, 2017-2024 (THOUSAND PROCEDURES)
  • TABLE 140 SPECT PROCEDURES MARKET, BY RADIOISOTOPE 2017-2024 (THOUSAND PROCEDURES)
  • TABLE 141 SPECT PROCEDURES MARKET, BY REGION, 2017-2024 (THOUSAND PROCEDURES)
  • TABLE 142 PET PROCEDURES MARKET, BY RADIOISOTOPE, 2017-2024 (THOUSAND PROCEDURES)
  • TABLE 143 PET PROCEDURES MARKET, BY REGION, 2017-2024 (THOUSAND PROCEDURES)
  • TABLE 144 THERAPEUTIC PROCEDURES MARKET, BY TYPE, 2017-2024 (THOUSAND PROCEDURES)
  • TABLE 145 THERAPEUTIC PROCEDURES MARKET, BY REGION, 2017-2024 (THOUSAND PROCEDURES)
  • TABLE 146 BETA EMITTER PROCEDURES MARKET, BY RADIOISOTOPE, 2017-2024 (THOUSAND PROCEDURES)
  • TABLE 147 BETA EMITTER PROCEDURES MARKET, BY REGION, 2017-2024 (THOUSAND PROCEDURES)
  • TABLE 148 ALPHA EMITTER PROCEDURES MARKET, BY REGION, 2017-2024 (THOUSAND PROCEDURES)
  • TABLE 149 BRACHYTHERAPY PROCEDURES MARKET, BY RADIOISOTOPE, 2017-2024 (THOUSAND PROCEDURES)
  • TABLE 150 BRACHYTHERAPY PROCEDURES MARKET, BY REGION, 2017-2024 (THOUSAND PROCEDURES)
  • TABLE 151 NUCLEAR MEDICINE MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 152 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 153 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 154 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 155 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 156 NORTH AMERICA: SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 157 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 158 NORTH AMERICA: PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 159 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 160 NORTH AMERICA: BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 161 NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 162 NORTH AMERICA: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 163 US: NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 164 US: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 165 US: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 166 US: SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 167 US: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 168 US: PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 169 US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 170 US: BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 171 US: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 172 US: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 173 CANADA: NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 174 CANADA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 175 CANADA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 176 CANADA: SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 177 CANADA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 178 CANADA: PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 179 CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 180 CANADA: BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 181 CANADA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 182 CANADA: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 183 APAC: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 184 APAC: NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 185 APAC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 186 APAC: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 187 APAC: SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 188 APAC: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 189 APAC: PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 190 APAC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 191 APAC: BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 192 APAC: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 193 APAC: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 194 JAPAN: NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 195 JAPAN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 196 JAPAN: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 197 JAPAN: SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 198 JAPAN: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 199 JAPAN: PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 200 JAPAN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 201 JAPAN: BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 202 JAPAN: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 203 JAPAN: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 204 CHINA: NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 205 CHINA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 206 CHINA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 207 CHINA: SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 208 CHINA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 209 CHINA: PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 210 CHINA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 211 CHINA: BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 212 CHINA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 213 CHINA: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 214 ROAPAC: NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 215 ROAPAC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 216 ROAPAC: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 217 ROAPAC: SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 218 ROAPAC: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 219 ROAPAC: PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 220 ROAPAC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 221 ROAPAC: BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 222 ROAPAC: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 223 ROAPAC: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 224 EUROPE: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 225 EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 226 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 227 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 228 EUROPE: SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 229 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 230 EUROPE: PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 231 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 232 EUROPE: BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 233 EUROPE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 234 EUROPE: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 235 GERMANY: NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 236 GERMANY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 237 GERMANY: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 238 GERMANY: SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 239 GERMANY: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 240 GERMANY: PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 241 GERMANY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 242 GERMANY: BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 243 GERMANY: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 244 GERMANY: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 245 FRANCE: NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 246 FRANCE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 247 FRANCE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 248 FRANCE: SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 249 FRANCE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 250 FRANCE: PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 251 FRANCE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 252 FRANCE: BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 253 FRANCE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 254 FRANCE: THERAPEUTIC APPLICATIONS MARKET, BY INDICATION, 2017-2024 (USD MILLION)
  • TABLE 255 UK: NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 256 UK: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 257 UK: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 258 UK: SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 259 UK: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 260 UK: PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 261 UK: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 262 UK: BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 263 UK: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 264 UK: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 265 ITALY: NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 266 ITALY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 267 ITALY: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 268 ITALY: SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 269 ITALY: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 270 ITALY: PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 271 ITALY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 272 ITALY: BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 273 ITALY: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 274 ITALY: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 275 SPAIN: NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 276 SPAIN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 277 SPAIN: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 278 SPAIN: SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 279 SPAIN: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 280 SPAIN: PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 281 SPAIN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 282 SPAIN: BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 283 SPAIN: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 284 SPAIN: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 285 ROE: NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 286 ROE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 287 ROE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 288 ROE: SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 289 ROE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 290 ROE: PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 291 ROE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 292 ROE: BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 293 ROE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 294 ROE: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 295 ROW: NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 296 ROW: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 297 ROW: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 298 ROW: SPECT APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 299 ROW: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 300 ROW: PET APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 301 ROW: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 302 ROW: BETA EMITTERS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 303 ROW: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 304 ROW: THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 305 PRODUCT LAUNCHES & APPROVALS (2017-2019)
  • TABLE 306 CONTRACTS (2017-2019)
  • TABLE 307 ACQUISITIONS (2017-2019)
  • TABLE 308 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS (2017-2019)

LIST OF FIGURES

  • FIGURE 1 RESEARCH METHODOLOGY: NUCLEAR MEDICINE MARKET
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 5 DATA TRIANGULATION METHODOLOGY
  • FIGURE 6 NUCLEAR MEDICINE MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
  • FIGURE 7 SPECT APPLICATIONS MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
  • FIGURE 8 PET APPLICATIONS MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
  • FIGURE 9 THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
  • FIGURE 10 HIGH PREVALENCE OF CANCER TO DRIVE THE MARKET DURING THE FORECAST PERIOD
  • FIGURE 11 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE NUCLEAR MEDICINE MARKET
  • FIGURE 12 SPECT PROCEDURES TO ACCOUNT FOR THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD
  • FIGURE 13 BETA EMITTERS TO ACCOUNT FOR THE LARGEST SHARE OF THE THERAPEUTIC NUCLEAR MEDICINE MARKET DURING THE FORECAST PERIOD
  • FIGURE 14 NUCLEAR MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 15 NORTH AMERICA TO DOMINATE THE NUCLEAR MEDICINE MARKET IN 2018
  • FIGURE 16 NORTH AMERICA: NUCLEAR MEDICINE MARKET SNAPSHOT
  • FIGURE 17 APAC: NUCLEAR MEDICINE MARKET SNAPSHOT
  • FIGURE 18 KEY DEVELOPMENTS IN THE NUCLEAR MEDICINE MARKET, 2017-2019
  • FIGURE 19 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018
  • FIGURE 20 NUCLEAR MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING (2018)
  • FIGURE 21 CARDINAL HEALTH: COMPANY SNAPSHOT (2018)
  • FIGURE 22 GE HEALTHCARE: COMPANY SNAPSHOT (2018)
  • FIGURE 23 LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT (2018)
  • FIGURE 24 BAYER AG: COMPANY SNAPSHOT (2018)
  • FIGURE 25 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2018)
目次
Product Code: PH 3590

"The nuclear medicine market is projected to grow at a CAGR of 4.7%."

The nuclear medicine market is projected to reach USD 5.2 billion by 2024 from an estimated USD 4.1 billion in 2019, growing at a CAGR of 4.7% during the forecast period. The key factors propelling the growth of this market are the increasing incidence and prevalence of cancer & cardiovascular diseases and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices have made it difficult for a section of end users to depend on nuclear medicine. These factors are expected to hamper the growth of the nuclear medicine market during the forecast period.

"The Technetium-99m segment to hold the largest share of SPECT radiopharmaceuticals market in 2019."

Based on type, the SPECT radiopharmaceuticals market is segmented Tc-99m, Tl-201, Ga-67, I-123, and other isotopes. In 2019, the Tc-99m segment is expected to command the largest share of the SPECT radiopharmaceuticals market. The large share of this segment can be attributed to the fact that Tc-99m is the most commonly used diagnostic radioisotope, which is used in around 80-90% of diagnostic scans and around 30 million patient examinations every year.

"In 2018, the thyroid indications segment accounted for the largest share of the therapeutics market."

On the basis of indication, the therapeutic nuclear medicine applications market is segmented into thyroid indications, bone metastasis, lymphoma, endocrine tumors, and other indications. In 2018, the thyroid indications segment accounted for the largest share of the therapeutics market. On the other hand, the endocrine tumors segment is expected to grow at the highest CAGR during the forecast period. The growth in this segment is majorly driven by the increasing use of therapeutic radiopharmaceuticals in the treatment of endocrine tumors.

"The Asia Pacific to witness the highest growth during the forecast period."

Asia Pacific is expected to grow at the highest CAGR during the forecast period of 2019-2024. The major factors driving the growth of the Asia Pacific market include research initiatives in Japan, rising installations of PET scanners in India and China, and initiatives by the Australian government.

Break of primary participants was as mentioned below:

  • By Company Type: Tier I: 55%, Tier II: 25%, Tier III: 20%
  • By Designation: C-Level Executives: 35%, Directors: 25%, Others: 40%
  • By Region: North America: 20%, Europe: 25%, Asia Pacific : 40%, RoW: 15%

Cardinal Health (US), GE Healthcare (US), and Curium (France) were the leading players in the nuclear medicine market.

Research Coverage

This report studies the nuclear medicine market based on type, application, procedural volume assessment, and region. The report also studies the different factors (such as drivers, restraints, and opportunities) affecting the market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and respective countries.

Key Benefits of Buying the Report

This report focuses on various levels of analysis-industry trends, market shares of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the nuclear medicine market, and their drivers, restraints, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the nuclear medicine market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 MARKET SCOPE
    • 1.2.2 MARKETS COVERED
    • 1.2.3 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH METHODOLOGY STEPS
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key insights from primary sources
    • 2.2.3 MARKET SIZE ESTIMATION METHODOLOGY
    • 2.2.4 REVENUE MAPPING-BASED MARKET ESTIMATION
  • 2.3 MARKET DATA ESTIMATION AND TRIANGULATION
  • 2.4 ASSUMPTIONS OF THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 NUCLEAR MEDICINE MARKET OVERVIEW
  • 4.2 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE AND COUNTRY (2019)
  • 4.3 DIAGNOSTIC PROCEDURES MARKET, BY TYPE, 2019 VS. 2024
  • 4.4 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2019 VS. 2024

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing incidence and prevalence of target conditions
      • 5.2.1.2 Alpha radioimmunotherapy-based targeted cancer treatment
      • 5.2.1.3 Initiatives to reduce the demand-supply gap of Mo-99
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Short half-life of radiopharmaceuticals
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Use of radiopharmaceuticals in neurological applications
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Hospital budget cuts and high equipment prices

6 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE

  • 6.1 INTRODUCTION
  • 6.2 DIAGNOSTIC NUCLEAR MEDICINE
    • 6.2.1 SPECT RADIOPHARMACEUTICALS
      • 6.2.1.1 Tc-99m
        • 6.2.1.1.1 Tc-99m commanded the largest share of the SPECT radiopharmaceuticals market in 2018
      • 6.2.1.2 I-123
        • 6.2.1.2.1 Reduced exposure to radiation and lower risk of patients developing radiation-induced cancer to drive the demand for I-123
      • 6.2.1.3 Tl-201
        • 6.2.1.3.1 TI-201 can be a potential substitute to Tc-99m
      • 6.2.1.4 Ga-67
        • 6.2.1.4.1 Overall sensitivity of a gallium scan is approximately 80% as a tumor-imaging agent, which is a key factor driving the growth of the Ga-67 market
      • 6.2.1.5 Other SPECT isotopes
    • 6.2.2 PET RADIOPHARMACEUTICALS
      • 6.2.2.1 F-18
        • 6.2.2.1.1 F-18 commanded the largest share of the PET radiopharmaceuticals market
      • 6.2.2.2 Rb-82
        • 6.2.2.2.1 Increasing number of PET procedures and high accuracy offered by the Rb-82 isotope to drive the growth of this market
      • 6.2.2.3 Other PET isotopes
  • 6.3 THERAPEUTIC NUCLEAR MEDICINE
    • 6.3.1 ALPHA EMITTERS
      • 6.3.1.1 Ra-223
        • 6.3.1.1.1 Easy production of Ra-223 is a key advantage driving market growth
    • 6.3.2 BETA EMITTERS
      • 6.3.2.1 Iodine-131
        • 6.3.2.1.1 Iodine-131 accounted for the largest share of the beta emitters market
      • 6.3.2.2 Y-90
        • 6.3.2.2.1 Increasing applications in treating hepatocellular carcinoma to propel the growth of this segment
      • 6.3.2.3 Sm-153
        • 6.3.2.3.1 Increasing incidence of bone metastasis to drive the growth of this segment
      • 6.3.2.4 Lu-177
        • 6.3.2.4.1 Increasing incidence of neuroendocrine cancer is a key factor driving the growth of this segment
      • 6.3.2.5 Re-186
        • 6.3.2.5.1 Re-186 is commonly used for bone pain relief
      • 6.3.2.6 Other beta emitters
    • 6.3.3 BRACHYTHERAPY ISOTOPES
      • 6.3.3.1 Iodine-125
        • 6.3.3.1.1 I-125 accounted for the largest share of the brachytherapy isotopes market
      • 6.3.3.2 Iridium-192
        • 6.3.3.2.1 Ir-192 is used in treating prostate cancer, skin cancer, sarcoids, and oral cancer
      • 6.3.3.3 Palladium-103
        • 6.3.3.3.1 Pd-103 is best suited to treat aggressive tumors
      • 6.3.3.4 Cesium-131
        • 6.3.3.4.1 Cs-131 is commonly used in gynecological applications
      • 6.3.3.5 Other brachytherapy isotopes

7 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 DIAGNOSTIC APPLICATIONS
    • 7.2.1 SPECT APPLICATIONS
      • 7.2.1.1 Cardiology
        • 7.2.1.1.1 Rising incidence of CVD has increased the demand for cardiac diagnostic scans
      • 7.2.1.2 Bone scans
        • 7.2.1.2.1 Precision of SPECT in bone scanning has driven dependence on the technology
      • 7.2.1.3 Thyroid applications
        • 7.2.1.3.1 Introduction of dual SPECT/CT imaging is an important trend in the thyroid applications segment
      • 7.2.1.4 Pulmonary scans
        • 7.2.1.4.1 SPECT/CT has shown high accuracy and sensitivity in pulmonary embolism applications
      • 7.2.1.5 Other SPECT applications
    • 7.2.2 PET APPLICATIONS
      • 7.2.2.1 Oncology
        • 7.2.2.1.1 Increasing cancer incidence will fuel market growth
      • 7.2.2.2 Cardiology
        • 7.2.2.2.1 Growing preference for FDG in cardiac imaging is likely to boost market growth
      • 7.2.2.3 Neurology
        • 7.2.2.3.1 Increasing incidence of AD, epilepsy, and Parkinson's disease is the major driver for the growth of the PET neurology market
      • 7.2.2.4 Other PET applications
  • 7.3 THERAPEUTIC APPLICATIONS
    • 7.3.1 THYROID INDICATIONS
      • 7.3.1.1 Increasing prevalence of thyroid disorders will fuel market growth
    • 7.3.2 BONE METASTASIS
      • 7.3.2.1 Introduction of novel therapies for bone metastasis will positively impact the market
    • 7.3.3 ENDOCRINE TUMORS
      • 7.3.3.1 The US dominates the therapeutic nuclear medicine market for endocrine tumor applications
    • 7.3.4 LYMPHOMA
      • 7.3.4.1 Development of new isotopes for the treatment of lymphoma presents huge growth opportunities
    • 7.3.5 OTHER INDICATIONS

8 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: PROCEDURAL VOLUME ASSESSMENT

  • 8.1 INTRODUCTION
  • 8.2 DIAGNOSTIC PROCEDURES
    • 8.2.1 SPECT PROCEDURES
    • 8.2.2 PET PROCEDURES
  • 8.3 THERAPEUTIC PROCEDURES
    • 8.3.1 BETA EMITTER PROCEDURES
    • 8.3.2 ALPHA EMITTER PROCEDURES
    • 8.3.3 BRACHYTHERAPY PROCEDURES

9 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    • 9.2.1 US
      • 9.2.1.1 The US holds the largest share of the North American market
    • 9.2.2 CANADA
      • 9.2.2.1 Investments to secure medical isotope supply are likely to boost market growth
  • 9.3 APAC
    • 9.3.1 JAPAN
      • 9.3.1.1 Japan dominates the APAC nuclear medicine market
    • 9.3.2 CHINA
      • 9.3.2.1 High incidence of cancer and strokes will support market growth in China
    • 9.3.3 REST OF ASIA PACIFIC
  • 9.4 EUROPE
    • 9.4.1 GERMANY
      • 9.4.1.1 The well-established healthcare system in Germany is a major factor supporting market growth in the country
    • 9.4.2 FRANCE
      • 9.4.2.1 France has a favorable reimbursement scenario for nuclear imaging
    • 9.4.3 UK
      • 9.4.3.1 Rising demand for nuclear imaging and growing awareness will drive the market in the UK
    • 9.4.4 ITALY
      • 9.4.4.1 Growing prevalence of cancer and CVD are likely to drive market growth in Italy
    • 9.4.5 SPAIN
      • 9.4.5.1 Initiatives by SEMNIM are likely to have a positive impact on the nuclear medicine market in Spain
    • 9.4.6 ROE
  • 9.5 REST OF THE WORLD

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 MARKET SHARE ANALYSIS
  • 10.3 COMPETITIVE LEADERSHIP MAPPING
    • 10.3.1 VISIONARY LEADERS
    • 10.3.2 INNOVATORS
    • 10.3.3 DYNAMIC DIFFERENTIATORS
    • 10.3.4 EMERGING COMPANIES
  • 10.4 COMPETITIVE SCENARIO
    • 10.4.1 PRODUCT LAUNCHES & APPROVALS
    • 10.4.2 CONTRACTS
    • 10.4.3 ACQUISITIONS
    • 10.4.4 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS

11 COMPANY PROFILES

(Business overview, Products offered, Recent developments, MNM view)*

  • 11.1 CARDINAL HEALTH
  • 11.2 CURIUM
  • 11.3 GE HEALTHCARE
  • 11.4 LANTHEUS MEDICAL IMAGING, INC.
  • 11.5 BAYER AG
  • 11.6 BRACCO IMAGING S.P.A.
  • 11.7 ECZACIBASI-MONROL NUCLEAR PRODUCTS
  • 11.8 NORDION, INC. (A SUBSIDIARY OF STERIGENICS INTERNATIONAL)
  • 11.9 ADVANCED ACCELERATOR APPLICATIONS (AAA) (A PART OF NOVARTIS)
  • 11.10 NTP RADIOISOTOPES SOC, LTD.

(A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION) 205

  • 11.11 JOINT STOCK COMPANY ISOTOPE (JSC ISOTOPE)
  • 11.12 NORTHSTAR MEDICAL RADIOISOTOPES, LLC
  • 11.13 ECKERT & ZIEGLER
  • 11.14 JUBILANT DRAXIMAGE, INC. (A SUBSIDIARY OF JUBILANT PHARMA)
  • 11.15 PHARMALOGIC
  • 11.16 INSTITUTE OF ISOTOPES CO., LTD.
  • 11.17 SINOTAU PHARMACEUTICALS GROUP
  • 11.18 ISOTOPIA MOLECULAR IMAGING LIMITED
  • 11.19 SHINE MEDICAL TECHNOLOGIES
  • 11.20 GLOBAL MEDICAL SOLUTIONS, LTD.
  • 11.21 RIGHT TO WIN

Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 AVAILABLE CUSTOMIZATIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.